Dalbavancin is being increasingly used for long-term treatment of subacute and/or chronic staphylococcal infections. Here we implemented and validated a new Bayesian model by means of the MwPharm software for accurately forecasting duration of pharmacodynamic target attainment above the efficacy thresholds of 4.02 or 8.04 mg/L against staphylococci. Forecasting accuracy improved substantially with the a posteriori approach compared to the a priori approach, especially when two measured concentrations were used. This strategy may help clinicians in estimating proper duration of optimal exposure with dalbavancin during longterm treatment.
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections / Cojutti, Pier Giorgio; Gatti, Milo; Punt, Nieko; Douša, Jiři; Zamparini, Eleonora; Tedeschi, Sara; Viale, Pierluigi; Pea, Federico. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - ELETTRONICO. - 63:1(2024), pp. 107038.1-107038.5. [10.1016/j.ijantimicag.2023.107038]
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections
Cojutti, Pier Giorgio
;Gatti, Milo;Tedeschi, Sara;Viale, Pierluigi;Pea, Federico
2024
Abstract
Dalbavancin is being increasingly used for long-term treatment of subacute and/or chronic staphylococcal infections. Here we implemented and validated a new Bayesian model by means of the MwPharm software for accurately forecasting duration of pharmacodynamic target attainment above the efficacy thresholds of 4.02 or 8.04 mg/L against staphylococci. Forecasting accuracy improved substantially with the a posteriori approach compared to the a priori approach, especially when two measured concentrations were used. This strategy may help clinicians in estimating proper duration of optimal exposure with dalbavancin during longterm treatment.File | Dimensione | Formato | |
---|---|---|---|
10.1016j.ijantimicag.2023.107038.pdf
embargo fino al 21/11/2024
Tipo:
Postprint
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
1.33 MB
Formato
Adobe PDF
|
1.33 MB | Adobe PDF | Visualizza/Apri Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.